Bristol-Myers Squibb Company (BMY)

BMY (NYSE:Drugs) EQUITY
$54.10
pos +0.08
+0.15%
Today's Range: 53.88 - 54.34 | BMY Avg Daily Volume: 9,802,900
Last Update: 05/22/17 - 4:00 PM EDT
Volume: 4,461,910
YTD Performance: -7.43%
Open: $54.02
Previous Close: $54.02
52 Week Range: $46.01 - $77.12
Oustanding Shares: 1,647,434,458
Market Cap: 88,994,409,421
6-Month Chart
TheStreet Ratings Grade for BMY
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 6 6 7
Moderate Buy 1 1 1 1
Hold 6 6 6 6
Moderate Sell 0 0 0 0
Strong Sell 1 1 2 2
Mean Rec. 2.21 2.21 2.40 2.31
Latest Dividend: 0.39
Latest Dividend Yield: 2.89%
Dividend Ex-Date: 04/05/17
Price Earnings Ratio: 18.76
Price Earnings Comparisons:
BMY Sector Avg. S&P 500
18.76 20.40 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-2.26% -23.56% 10.86%
GROWTH 12 Mo 3 Yr CAGR
Revenue 17.30 0.20 0.06
Net Income 176.30 0.80 0.20
EPS 184.90 0.70 0.19
Earnings for BMY:
EBITDA 5.01B
Revenue 19.43B
Average Earnings Estimates
Qtr (06/17) Qtr (09/17) FY (12/17) FY (12/18)
Average Estimate $0.74 $0.75 $2.94 $3.06
Number of Analysts 8 7 11 9
High Estimate $0.76 $0.78 $2.97 $3.20
Low Estimate $0.72 $0.71 $2.87 $2.77
Prior Year $0.69 $0.77 $2.83 $2.94
Growth Rate (Year over Year) 6.70% -3.15% 3.76% 4.25%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
RMPIA
By

Jim Cramer

 | May 16, 2017 | 12:30 PM EDT
What's right for a hedge fund manager sitting on a big gain, isn't necessarily right for you.

bearishBristol-Myers Cut to Underperform at BMO

May 3, 2017 | 9:08 AM EDT
Bristol-Myers was cut to "Underperform" at BMO with a $47 price target.

bearishBristol-Myers Cut to Underperform at BMO

May 3, 2017 | 9:08 AM EDT
Bristol-Myers was cut to "Underperform" at BMO with a $47 price target.
By

Bret Jensen

 | Apr 28, 2017 | 4:01 PM EDT
Let the weekend begin and may Day 2 and 3 of the NFL draft bring my Arizona Cardinals some undervalued gems on both sides of the bay. Great filling for Doug Kass over the past couple of days. Look forward to doing it again.
RMPIA
By

Jim Cramer

 | Apr 27, 2017 | 3:48 PM EDT
It doesn't look like Washington will be much help.
By

Bret Jensen

 | Apr 27, 2017 | 10:09 AM EDT
The market is off to a decent start as investors try to digest scores of first-quarter earnings reports. Bristol-Myers Squibb (BMY) is just one of many large-cap drug and biotech companies reporting today. BMY shares are up as earnings and revenue easily surpassed estimates, powered by Opdivo growth. AbbVie (ABBV) also is up nicely. Its oncology product Imbruvica posted an almost 45% rise in year-over-year sales while Humira continues to see sales growth in the mid-teens
By

Dick Arms

 | Apr 25, 2017 | 7:00 AM EDT
S&P is already at resistance levels, where the advance appeared to stall.
By

Skip Raschke

 | Apr 19, 2017 | 8:45 AM EDT
Consider this BMY bullishly biased, near-the-money vertical call spread.
RMPIA
By

Doug Kass

 | Apr 10, 2017 | 4:36 PM EDT
- Rev Shark, Yes, Market Lacks Fear, but There's No Emotion Either Several columns from me on the same theme today:   * I Fear the Absence of Fear of Loss  * More Wall Street Nonsense on Display  * Meshuganah Is Trump  * Thinking and Trading Opportunistically on the Short Side   Trade of the Week - Long a current fave - Allergan AGN!
RMPIA
By

Jim Cramer

 | Apr 3, 2017 | 4:04 PM EDT
It's pretty normal to have profit-taking after such a strong first quarter.
we have a beauty here, we'll roll it up SOLD XLNX JUN 65 CALL AT 3.6 (in a...
we have a nice winner, we'll roll up SOLD MOMO JUL 40 CALL AT 7.1 (in at 4.2) BOUGHT...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.